- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07943468
Extended Platelet-Rich Fibrin Membrane Versus Resorbable Novel Magnesium Membrane for Horizontal Ridge Augmentation With Simultaneous Implant Placement
Effectiveness Of Extended Platelet-Rich Fibrin Membrane Versus Resorbable Novel Magnesium Membrane for Horizontal Ridge Augmentation With Simultaneous Implant Placement
This study performed to evaluate and compare the effectiveness ofextended platelet-rich fibrin (ePRF) and novel magnesium membrane in horizontal ridge augmentation with simultaneous implant placement clinically and radiographically
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The phenomenon of horizontal and vertical ridge resorption, following tooth extraction, has been extensively investigated. Different augmentation techniques have been developed to overcome this phenomenon on localization, extent, and configuration of the bone defect. These include insertion of bone grafts or barrier membranes in terms of guided bone regeneration.
The advancement Of guided bone regeneration has significantly expanded the range of implant applications to be a highly reliable treatment option even in areas of the jaw bone don't have sufficient bone support.The predictability that just attained if this process is successful, it could change the treatment of a compromised patient into a nearly normal challenge. Various have described to reconstruct deficient alveolar ridges. In the simultaneous treatment approach, guided bone regeneration is associated with superior outcomes when compared to other procedures and has become the treatment Of choice to provide optimal support for dental implants.
The primary alternative to an autograft is the use of allograft materials, which can obtained from either a compatible living donor or from cadaveric bone sources. Allograft materials can be prepared in three primary forms: fresh, frozen, or freeze-dried. Fresh and frozen allograft materials possess superior osteoinductive but are rarely used nowadays due to the higher risk Of a host immunogenic response, limited shelf life, and increased risk of disease transmission. Further processing of allograft material through freeze-drying can increase the shelf life of the material and decrease the immunogenicity, though at the cost of decreased osteoinductive potential, decreased structural strength, and osseointegration. Allografts have been successfully used for guided bone regeneration in bone augmentation procedure. This study performed to evaluate and compare the effectiveness of extended platelet-rich fibrin and novel magnesium membrane in horizontal ridge augmentation with simultaneous implant placement clinically and radiographically
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Al Mansurah, Egypten
- Mansoura university
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Horizontal bone width <6 mm an s than 3 mm at crest
- Sufficient vertical bone height for implant placement.
- Healthy and sufficient width Of keratini7Æd mucosa.
- Maxillary or mandibular edentulous space sufficient for prosthesis according to teeth to be restored. All patients are between 18 and 60 years
Exclusion Criteria:
- General contraindication for implant placement and/or surgical treatment.
- Ongoing Inflammatory and/or autoimmune disease of the oral cavity.
- Immunosuppressant, corticosteroid or bisphosphonate therapy.
- History of malignancy, radiotherapy or chemotherapy for treatment of malignancy within the past 5 years.
- Smokers.
- Insulin- dependent diabetes
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Group l
Group l: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration and pericardium membrane (maxxeus). |
Group l: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by freeze dried bone allograft (maxgraft granules, botiss biomaterials GmbH, Berlin, Germany, part of Straumann Group, Basel, Switzerland) and pericardium membrane (maxxeus). |
|
Experimentell: Group II
Group II: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by dried freeze allograft and (e-PRF) membrane |
Group II: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by freeze dried bone allograft part of Straumann Group, Basel, Switzerland) and (e-PRF) membrane. |
|
Experimentell: Group III
Group III: It will include 10 patients and they will treated with delayed implant placement combined with GBR by dried freeze bone allograft DFBA and novel magnesium membrane NOVAMag |
roup III: It will include 10 patients and they will treated with delayed implant placement combined with guided bone regeneration by dried freezed bone allograft (maxgraft granules, botiss biomaterials GmbH, Berlin, Germany, part of Straumann Group, Basel, Switzerland) and novel magnesium membrane NOVAMag |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Radiographic assessment by cone beam computed tomography
Tidsram: immediately postoperatively , at the 5-8 months postoperative and at one year postoperative
|
immediately postoperatively , at the 5-8 months postoperative and at one year postoperative
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Status of the peri-implant soft tissues (probing depth )
Tidsram: 2 months and 6 months after loading.
|
2 months and 6 months after loading.
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- A010120230M
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
It will be available if it needed
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .